ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
Agendia’s proven breast cancer recurrence assay, MammaPrint, now available in the Middle East
Agendia signs partnership agreement with Cryogene and Mist for Middle East distribution IRVINE, CA and AMSTERDAM, 8 November 2016 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today a Read More
Agendia Announces the Award of a New Category 1 CPT Code from the American Medical Association for the MammaPrint 70-Gene Breast Cancer Recurrence Assay
The company also announces new patient awareness platform to help aid in breast cancer treatment decisions IRVINE, CA and AMSTERDAM – 1, November 2016 – Agendia, Inc., a world leader in personalized medicine and molecular Read More
Agendia Expands its Business Activities in Germany
The “BRIDGE” initiative offers German patients free access to Agendia’s MammaPrint® breast cancer recurrence assay Data from the MINDACT trial shows MammaPrint is the only test on the German market supported by the highest level Read More
Agendia appoints three leading cancer physicians to its Medical Advisory Board
IRVINE, CA and AMSTERDAM – 12 October 2016 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today the appointment of three new members to its Medical Advisory Board. Prof. Read More